Eli Lilly will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, showing big pharma’s increasing interest in psychedelics.
Eli Lilly said on Thursday it will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, in a move that further spotlights big pharma’s increasing …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be…
Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its…
The AtaiBeckley acquisition would be the largest psychedelic deal to date.
Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and…
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
Eli Lilly is reportedly negotiating to acquire psychedelic drugmaker AtaiBeckley. AtaiBeckley shares experienced a significant…
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
Eli Lilly agrees to $3.8B psychedelic buy
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
Weight-loss drugmaker Lilly nears $1.97 bn AtaiBeckley's acquisition: Report
AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal - Eli Lilly (NYSE:LLY), AtaiBeckley (N
AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Eli Lilly Acquisition Talks - Eli Lilly (NYSE:LLY)
Eli Lilly punta sugli psichedelici: acquisirà AtaiBeckley per 2,8 miliardi di dollari | MilanoFinanza News
Eli Lilly scommette sulla salute mentale: acquisita AtaiBeckley per 2,8 miliardi di dollari
